Protective effect of melatonin on 3-nitropropionic acid-induced oxidative stress in synaptosomes in an animal model of Huntington's disease

Journal of Pineal Research

Volumn 37, Issue 4, 2004, Pages 252-256

  Túnez, Isaac ^a   Montilla, Pedro ^a   Muñoz, M Del Carmen ^a   Feijóo, Montserrat ^a   Salcedo, Manuel ^a  

^a Universidad de Cordoba   (Spain)

Author keywords

3 nitropropionic acid; Free radical scavenger; Huntington's disease; Melatonin; Oxidative stress; Synaptosomes

Indexed keywords

3 NITROPROPIONIC ACID; CARBONYL DERIVATIVE; MELATONIN; SUCCINATE DEHYDROGENASE; SUPEROXIDE DISMUTASE;

ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; BRAIN CORTEX; BRAIN REGION; CONTROLLED STUDY; CORPUS STRIATUM; ENZYME ACTIVITY; HUNTINGTON CHOREA; LIPID PEROXIDATION; MALE; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PROPHYLAXIS; PROTEIN CONTENT; RAT; SYNAPTOSOME;

ANIMALS; ANTIOXIDANTS; BRAIN; DISEASE MODELS, ANIMAL; HUNTINGTON DISEASE; LIPID PEROXIDATION; MALE; MELATONIN; NEUROPROTECTIVE AGENTS; NITRO COMPOUNDS; OXIDATIVE STRESS; PROPIONIC ACIDS; RATS; RATS, WISTAR; SUCCINATE DEHYDROGENASE; SUPEROXIDE DISMUTASE; SYNAPTOSOMES;

EID: 7644237780     PISSN: 07423098     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-079X.2004.00163.x     Document Type: Article

References (41)

1. MATTSON MP. Excitotoxic and excitoprotective mechanisms: abundant targets for the prevention and treatment of neurodegenerative disorders. Neuromol Med 2003; 3:65-94.
2. DAVIES S, RAMSDEN DB. Huntington's disease. Mol Pathol 2001; 54:409-413.
3. ALBIN RL, REINER A, ANDERSON KD et al. Striatal and nigral neuron subpopulation in rigid Huntington's disease: implication for the functional anatomy of chorea and rigidity-akinesia. Ann Neurol 1990; 27:357-365.
4. MARTIN JB, GUSELLA JF. Huntington's disease: pathogenesis and management. N Engl J Med 1986; 315:1267-1276.
5. BORLANGAN CV, KOUTOUZIS TK, SANBERG PR. 3-Nitropropionic acid animal model and Huntington's disease. Neurosci Lett 1998; 251:173-176.
6. BROUILLET E, CONDÉ F, BEAL MF, HANTRAYE P. Replicating Huntington's disease phenotype in experimental animals. Prog Neurobiol 1999; 59:427-468.
7. MONTILLA P, TU̇NEZ I, MUÑOZ MC et al. Effect of glucocorticoids on 3-nitropropionic acid-induced oxidative stress in synaptosomes. Eur J Pharmacol 2004; 488:19-25.
8. LA FONTAINE MA, GEDDES JW, BANKS A, BUTTERFIELD DA. 3-Nitropropionic acid induced in vivo protein oxidation in striatal and cortical synaptosomes: insights into Huntington's disease. Brain Res 2000; 858:356-362.
9. LA FONTAINE MA, GEDDES JW, BANKS A, BUTTERFIELD DA. Effect of exogenous and endogenous antioxidants on 3-nitropropionic acid-induced in vivo oxidative stress and striatal lesions: insights into Huntington's disease. J Neurochem 2000; 75:1709-1715.
10. LAFONTAINE MA, GEDDES JW, BUTTERFIELD DA. 3-Nitropropionic acid-induced changes in bilayer fluidity in synaptosomal membranes: implications for Huntington's disease. Neurochem Res 2002; 27:507-511.
11. GUTEKUNST CA, NORFLUS F, HERSCH SM. Recent advances in Huntington's disease. Curr Opin Neurol 2000; 13:445-450.
12. REITER RJ. Oxidative damage in the central nervous system: protection by melatonin. Prog Neurobiol 1998; 56:359-384.
13. MILLER JW, SELHUB J, JOSEPH JA. Oxidative damage caused by free radicals produced during catacholamine autoxidation: protective effects of O-methylation and melatonin. Free Rad Biol Med 1996; 21:241-249.
14. TAN DX, CHEN LD, POEGGELER B et al. Melatonin: a potent, endogenous hydroxyl radical scavenger. Endocrine J 1993; 1:57-60.
15. RODRÍGUEZ C, MAYO JC, SAINZ RM et al. Regulation of antioxidant enzymes: a significant role for melatonin. J Pineal Res 2004; 36:1-9.
16. REITER RJ, CABRERA J, SAINZ RM et al. Melatonin as a pharmacological agent against neuronal loss in experimental models of Huntington's disease, Alzheimer's disease and Parkinsonism. Ann N Y Acad Sci 1999; 890:471-484.
17. REITER RJ. Melatonin, active oxygen species and neurological damage. Drug News Perspect 1998; 11:291-296.
18. MONTILLA-LÓPEZ P, MUÑOZ-ÁGUEDA MC, FEIJÓO-LÓPEZ M et al. Comparison of melatonin versus vitamin C on oxidative stress and antioxidant enzyme activity in Alzheimer's disease induced by okadaic acid in neuroblastoma cells. Eur J Pharmacol 2002; 451:237-243.
19. TÚNEZ I, MUÑOZ MC, FEIJÓO M et al. Protective melatonin effect on oxidative stress induced by okadaic acid into rat brain. J Pineal Res 2003; 34:265-268.
20. SPRINGERE JE, AZBILL RD, CARLSON SL. A rapid and sensitive assay for measuring mitochondrial metabolic activity in isolated neural tissue. Brain Res Protoc 1997; 2:259-263.
21. LEVINE RL, GARLAND D, OLIVIER CN et al. Determination of carbonyl content in oxidatively modified proteins. Meth Enzymol 1990; 186:464-478.
22. PATTICHIS K, LOUCA L, GLOVER V. Quantitation of soluble superoxide dismutase in rat strata, based on the inhibition of nitrite formation from hydroxylammonium chloride. Anal Biochem 1994; 221:428-431.
23. STRACK A, DUFFY CF, MALVEY M, ARRIAGA EA. Individual mitochondrion characterization: a comparison of classical assays to capillary electrophoresis with laser-induced fluorescence detection. Anal Biochem 2001; 294:141-147.
24. LOWRY OH, ROSEBROUGH HJ, FARR AL, RANDALL RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193:265-275.
25. BINIENDA ZK. Neuroprotective effects of L-carnitine in induced mitochondrial dysfunction. Ann N Y Acad Sci 2003; 993:289-295.
26. BINIENDA ZK, ALI SF. Neuroprotective role of L-carnitine in the 3-nitropropionic acid induced neurotoxicity. Toxicol Lett 2001; 125:67-73.
27. BINIENDA ZK, SIMMONS C, HUSSAIN S et al. Effect of acute exposure to 3-nitrppropionic acid on activities of endogenous antioxidants in the rat brain. Neurosci Lett 1998; 251:173-176.
28. ROSENSTOCK TR, CARVALHO AC, JURKIEWICZ A et al. Mitochondrial calcium, oxidative stress and apoptosis in neurodegenerative disease model induced by 3-nitropropionic acid. J Neurochem 2004; 88:1220-1228.
29. BORLONGAN CV, YAMAMOTO M, TAKEI N et al. Glial cell survival is enhanced during melatonin-induced neuroprotection against cerebral ischemia. FASEB J 2000; 14:1307-1317.
30. ACUÑA-CASTROVIEJO D, MATÍN M, MACÍA M et al. Melatonin, mitochondrial, and cellular bioenergetics. J Pineal Res 2001; 30:54-74.
31. LEÓN J, ACUÑA-CASTROVIEJO D, SAINZ RM et al. Melatonin and mitochondrial function. Life Sci 2004; 75:765-790.
32. MARTÍN M, MACÍA M, LEÓN J et al. Melatonin increases the activity of the oxidative phosphorylation enzymes and the production of ATP in rat brain and liver mitochondria. Int J Biochem Cell Biol 2002; 34:348-357.
33. MARTÍN M, MACÍAS M, ESCAMES G et al. Melatonin-induced increased activity of the respiratory Cain complexes I and IV can prevent mitochondrial damage induced by ruthenium red in vivo. J Pineal Res 2000; 28:242-248.
34. MARTÍN M, MACÍAS M, ESCAMES G et al. Melatonin but not vitamins C and E maintains glutathione homeostasis in t-butyl hydroperoxide-induced mitochondrial oxidative damage. FASEB J 2000; 14:1677-1679.
35. OKATANI Y, WAKATSUKI A, REITER RJ et al. Protective effect of melatonin against mitochondrial injury induced by ischemia and reperfusion of rat liver. Eur J Pharmacol 2003; 469:145-152.
36. WAKATSUKI A, OKATANI Y, SHINOHARA K et al. Melatonin protects fetal rat brain against oxidative mitochondrial damage. J Pineal Res 2001; 30:22-28.
37. REITER RJ, TAN DX, QI W et al. Pharmacology and physiology of melatonin in the reduction of oxidative stress in vivo. Biol Signals Recept 2000; 9:160-171.
38. DIGNER HP, HABERKORN U, KINSCHERF R. Apoptosis modulators in the therapy of neurodegenerative diseases. Expert Opin Invest Drugs 2000; 9:747-764.
39. REITER RJ, CABRERA J, SAINZ RM et al. Melatonin as pharmacological agent against neuronal loss in experimental models of Huntington's disease, Alzheimer's disease and parkinsonism. Ann N Y Acad Sci 1999; 890:471-485.
40. BENITEZ-KING G, TUNEZ I, BELLON A et al. Melatonin prevents cytoskeletal alterations and oxidative stress induced by okadaic acid in N1E-115 cells. Exp Neurol 2003; 182:151-159.
41. CHUNG SY, HAN SH. Melatonin attenuates kainic acid-induced hippocampal neurodegeneration and oxidative stress through microglial inhibition. J Pineal Res 2003; 34:95-102.